Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study
Telitacicept demonstrated significant efficacy in refractory AChR+ gMG and may reduce dependence on traditional immunosuppressants. These real-world findings support its use as a valuable treatment choice for this challenging patient group.
Authors
- Meijie Qu (ORCID: https://orcid.org/0000-0003-1944-0455)
- Ming Liu (ORCID: https://orcid.org/0000-0002-1114-1728)
- Liwei Jiang (ORCID: https://orcid.org/0000-0003-0034-6733)
- Xupeng Sun
- Li Wang
- Xi Rong
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3389/fimmu.2026.1752245
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00